Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company developing medicines targeting genetically determined dependencies within the chromatin regulatory system using its Gene Traffic Control platform. Foghorn Therapeutics has a research collaborationsand license agreements with Merck and Loxo Oncology.the company was incorporated in 2015 and is headquartered in Cambridge, MA.
Name / Ticker | Price | Zen Rating |
---|---|---|
$7.77 | A | |
$22.48 | A | |
$40.37 | A |